RE:RE:RE:RE:RE:RE:Polish Researchers Cite Rutherrin PDT for Brain CancerRight, the glass half full view is that a small pp is just a cash bridge to an imminent regional licensing deal announcement, which shores up all liquidity needs until they achieve BTD approval (likely in Q1 based on the recent MD&A). The half empty view is the Rolodex and investor appetite is currently tapped out regardless of the very strong data, which seems a little implausible.